Skip to content

Revvity RVTY INDIA — Revenue from Contract with Customer, Excluding Assessed Tax

Discontinued — last reported Q4 '20

Similar metrics at other companies

Verisk Analytics, Inc. logo
VRSKUS — Revenue
$638.4M+2.7%
Verisk Analytics, Inc. logo
VRSKOther Countries — Revenue
$78.9M+10.3%
Incyte logo
INCYNon Us — Revenue
$55.23M+99.2%
PTC logo
PTCDE — Revenue
$92.2M+11.6%
Fortive logo
FTVDE — Revenue
$57.6M-1.2%
Roivant Sciences logo
ROIVProduct — Revenue
$18.37M+10.3%

Other financials

Income statement

See full
Revenue$711.1M+7.0%
Gross profit$387.7M+3.2%
Operating income$75.9M+5.1%
Net income$40.7M-3.6%
EPS (diluted)$0.36+2.9%

Balance sheet

See full
Cash & equivalents$861.5M-24.3%
Total debt$3.9B+17.8%
Total equity$7.2B-5.9%
Total assets$12.0B-2.9%

Cash flow

See full
Operating cash flow$115.2M-10.1%
CapEx$19.8M+23.7%
Free cash flow$95.5M-14.9%

Valuation

See full
Market cap$11.16B-22.9%
Enterprise value$14.24B-13.7%
P/E46.5×-4.0×
P/S3.8×-1.4×

Profitability

See full
Gross margin48.5%
Operating margin12.4%-1.1pp
Net margin8.3%-2.1pp
FCF margin17%-1.9pp

Returns & leverage

See full
Return on equity3.2%-0.5pp
Debt / equity0.5×+0.1×
Current ratio1.7×-1.9×

Where this comes from

Reported directly by Revvity in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Revvity’s 10-K, filed March 2, 2021, on SEC EDGAR. View the filing →

Questions, answered.

What does INDIA — revenue from contract with customer, excluding assessed tax mean?
The total sales revenue earned from customers located in India, excluding taxes.
How do you interpret INDIA — revenue from contract with customer, excluding assessed tax?
An increase indicates growing market demand and successful commercial execution in the region, while a decrease may signal competitive pressure or economic headwinds.
How does INDIA — revenue from contract with customer, excluding assessed tax compare across companies?
Comparable to geographic revenue reporting by multinational life science and diagnostics peers, often benchmarked against regional GDP growth and healthcare spending trends.